Imfinzi improves overall survival at interim
This announcement contains inside information 27 June 2019 07:00 BST Imfinzi improves overall survival at interim analysis in the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer Trial showed statistically-significant and clinically-meaningful benefit in patients with the most aggressive type of lung cancer AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for